Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.

Medicare is the lead US payer for Alzheimer's drugs. • Source: Shutterstock

More from Market Access

More from Pink Sheet